Email us: firstname.lastname@example.org
RENO, Nev., March 1, 2012. – First Warning Systems, Inc. announces a Predictive Analytics software strategy to provide Clinician Decision Support for early stage breast cancer indications. In clinical trials, the First Warning system has demonstrated 90% accuracy using neural algorithms in the laboratory. “I believe major improvements in our health care delivery system can be realized by evidence-based analytics that can be modeled and delivered to clinicians to accelerate breast cancer care based on the earliest detection possible.” says, Jim Holmes, First Warning Chairman/CEO.
The First Warning 510k approved device, to collect deep tissue breast temperatures, is being upgraded to interface to predictive analytics modeling software to utilize large databases of patient records to indicate abnormalities in the tumor microenvironment up to six years prior to detection by current technologies.
“First Warning truly is the leader in bringing this disruptive technology that combines the fields of predictive analytics, biometrics software and deep tissue temperature sensing into an early detection system that will dominate the early detection women’s breast health field.” adds, Holmes. “And will significantly improve the medical economics for early detection and delivery to marginalized women everywhere including third world countries.”
About First Warning Systems Process
Temperature readings of breast tissue create Dynamic Thermal Finger Prints (DTFP) which are correlated to dysfunctional circadian genes. Multiple bioinformatics algorithms compare DTFPs to the circadian gene protein profiles to identify breast tissue abnormalities at different stages of development of disturbed breast cancerous cells. FWS delivers a report to the primary care physician with industry leading 90% accuracy. The FWS process is the only detection process that identifies abnormalities before a tumor presents, can be used by a primary care physician, and delivers results while the patient is in the office. The capital investment is very competitive, also requires a minimal data interpretation fee.
About First Warning Systems
First Warning Systems, (FWS) founded in 2008, based in Reno, NV. FWS’s principal shareholder is Lifeline Biotechnologies, Inc (OTC Market: LLBO). FWS holds the exclusive development, manufacturing and marketing worldwide license from Lifeline, to commercialize the intellectual property. The FWS product line is a device and process that detects breast tissue abnormalities which lead to health risk assessment and management and potentially, breast cancer. Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols. FWS is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS product as well as obtaining a Euro CE Mark for marketing in the UK, EU and Russia markets.
For more information, contact:
Jim Holmes, CEO 775-324-3822